Industrial Biotechnology Innovation Cluster

工业生物技术（IB）是一套跨学科的技术，利用生物资源生产和加工日常产品，如食品、燃料和药品。该领域有望大幅增长，仅在英国就有可能颠覆价值超过340亿英镑的市场。消费者需求、政府碳排放目标、原料生产效率、基础和技术创新等因素的共同作用，为该行业的大幅扩张创造了完美的局面。这种模式的转变利用了广泛的科学和工程学科的优势，这些学科构成了利用该行业快速、专业化和竞争性增长的基础。工业生物技术是英格兰西北部（NW）拥有临界质量并迅速成为世界领先集群的一个领域。该地区拥有一些全球最大的医疗保健和生物制药公司，包括阿斯利康（AstraZeneca）、梯瓦（Teva）、克罗达（Croda）和联合利华（Unilever）。生物制剂的首次商业化生产是在斯派克，由礼来（Eli Lilly）生产胰岛素。西北地区有几个中小企业创新区，包括达斯伯里、利物浦知识区和奥尔德利公园，这是英国最大的单一地点生命科学园区。IB在该地区拥有2.5万名员工，营业额超过60亿英镑。高等教育部门也在蓬勃发展，并因其国际领先的IB研究和独特的设施而得到认可，这些设施专为创新而建。最近，曼彻斯特大学的高等教育女王周年奖证明了这一点，该奖项认可了曼彻斯特生物技术研究所世界领先的生物技术专业知识，为生物工业革命指明了方向。翻译IB以满足迫切的社会需求不会自发发生；综合战略、转化活动集群和创新生态系统至关重要。西北地区的组织、知识、技能和设施已经证明可以促进联系和合作，使该地区的组织能够更灵活、更有效地运作。在这里，我们将集中和建立我们在学术界、商界、民间合作伙伴、加速器、投资者和民间社会创意方面的区域优势，并建立工业生物技术创新集群（IBIC），目的是加速我们的产出的商业开发，并产生经济、社会和科学影响。在道德、多样性和开放的文化氛围下，该集群将为企业提供尖端的研发知识、能力和基础设施，以及创新融资、技能培训和专家支持和建议。IBIC将由曼彻斯特大学领导，总部设在曼彻斯特的新创新区，位于北部不断增长的经济中心。它是与利物浦大学以及我们更广泛的公民和商业合作伙伴共同创建的。它完全符合大曼彻斯特和利物浦公民合作伙伴的战略，以增加利益，加速基础研究在整个地区的影响，更广泛地说，英国经济和社会。IBIC将使英国实现其成为全球生物技术研究和创新超级大国的雄心。IBIC预计将直接刺激250万英镑的现金和400万英镑的实物共同投资，建立150个合作项目，培训200多名学生进入IB的职业生涯，创造多达100个绿色工作岗位，并建立20多个新的商业企业，为西北地区吸引1000万英镑的投资，在中期产生至少3:1的公共投资经济回报。它将帮助IBIC成为一个独立的、以企业为主导的卓越集群，并使社会能够克服能源安全、疾病和减轻饥饿方面的挑战，从而留下长期的遗产。

Industrial Biotechnology (IB) is a set of cross-disciplinary technologies that uses biological resources for producing and processing everyday products such as food, fuels, and medicines. The field is poised for dramatic growth and has the potential to disrupt markets worth more than £34bn in the UK alone. A confluence of consumer demand, Government carbon emission targets, feedstock production efficiencies, fundamental and technical innovation has created a perfect situation for the industry to significantly expand. This paradigm shift capitalises on the strengths of a vast range of scientific and engineering disciplines which form the foundation for leveraging the rapid, specialised, and competitive growth of the sector. Industrial Biotechnology is an area in which the North-West (NW) of England has critical mass and is rapidly emerging as a world leading cluster. The region is home to some of the world's biggest healthcare and biomanufacturing companies, including AstraZeneca, Teva, Croda and Unilever, and the first commercial production of a biologic was in Speke with Eli Lilly's manufacture of insulin. The NW is home to several SME innovation zones, including Daresbury, Liverpool Knowledge Quarter and Alderley Park, which is the UK's largest single site life science campus. IB in the region employs 25,000 people and has a turnover of over £6Bn. The HEI sector is also thriving and recognised for its internationally leading IB research and unique facilities, purpose-built for innovation. Most recently demonstrated by the University of Manchester's Queens Anniversary Prize for higher education, which recognised the world-leading biotechnology expertise of the Manchester Institute of Biotechnology that sign-posts towards a bio industrial revolution. Translating IB to meet urgent societal needs will not happen spontaneously; an integrated strategy, cluster of translational activity and innovation ecosystem are essential. The NW has co-location of organisations, knowledge, skills and facilities which have already demonstrated they can promote connection and collaboration - enabling those in the region to operate more flexibly and productively. Here, we will concentrate and build our regional strengths in academia, business, civic partners, accelerators, investors and creatives with civil society and establish the Industrial Biotechnology Innovation Cluster (IBIC) with the aim of accelerating commercial exploitation of our outputs and delivering economic, social and scientific impact. United by a culture of ethics, diversity, and openness, the cluster will provide businesses with access to cutting-edge R&D knowledge, capabilities and infrastructure as well as innovation finance, skills training, and specialist support and advice. IBIC will be led by The University of Manchester and headquartered in the new Innovation District in Manchester - at the heart of the north's growing economy. It has been co-created with the University of Liverpool and our wider Civic and Business Partners. It is fully aligned with Greater Manchester and Liverpool Civic Partners strategies to increase the benefit and accelerate the impact of fundamental research across the region, and more broadly the UK economy and society. IBIC will enable the UK to realise its ambition to be a global biotechnology research and innovation superpower. The IBIC is expected to directly stimulate £2.5M cash and £4M in-kind co-investment, establish 150 collaborative projects, train 200+ students to enter careers within IB, create up to 100 green jobs, and establish 20+ new commercial ventures attracting a further £10M in investment to the North-West, generating as a minimum 3:1 economic return to public investment over the medium term. It will have a long-term legacy by helping establish IBIC as an independent and business-led cluster of excellence and by enabling society to overcome challenges in energy security, disease, and hunger mitigation.